Costa Brava Partnership III, L.P. Letter to Shareholders: Independent Proxy Advisory Firms Recommend That Shareholders of Bradley Pharmaceuticals Vote Costa Brava's BLUE Proxy Card and Not Management's Card

    BOSTON, Oct. 20 /PRNewswire/ -- Costa Brava Partnership III, L.P. sent
 the following letter, today, to the shareholders of Bradley
 Pharmaceuticals, Inc.:
     Dear Fellow Shareholders:
     Time is short. The Annual Meeting is just days away and the future
 direction of Bradley Pharmaceuticals, Inc. (NYSE:   BDY) is at stake. Your
 vote is extremely important, no matter how many or how few shares you own.
 We urge you to vote now by phone or internet by following the instructions
 on your BLUE proxy card today. If you no longer have your BLUE proxy card,
 please follow the instructions at the end of this letter.
     You've heard from us and you've heard from Bradley management. Do not
 be misled by the vague promises and slick materials sent out by Dan
 Glassman and Bradley. And don't just take our word that our nominees are
 the right choice. Listen to recommendations of two leading independent
 proxy advisory firms, which gave each side equal time to make its case.
 After listening to both sides, Glass Lewis & Co. concluded, "In our
 opinion, the new Costa Brava directors will hold management accountable for
 its stated initiatives to strengthen its internal controls and enhance
 shareholder value." Institutional Shareholder Services said that, "Mr. Seth
 Hamot and Mr. Douglas Linton would better represent shareholder interest."
     Again, these are the leading independent proxy advisory firms in the
 country. They conducted an in-depth analysis, listened to both sides, and
 reached their own conclusions.
     We are pleased that both of these independent companies acknowledged
 not only Bradley's problems in corporate governance, executive compensation
 and director independence but also recognized that our nominees will
 actively contribute to the solution. (If you want to better understand
 these two proxy advisors' missions, we encourage you to view their websites
 at http://www.issproxy.com and http://www.glasslewis.com.)
     Here is a sampling of what the firms had to say in recommending that
 shareholders support Costa Brava's nominees and proposals by voting the
 BLUE proxy card:
     Our Nominees
     In praise of nominees Hamot and Linton, ISS cited, "Seth Hamot's
 private equity/finance experience," and Doug Linton's, "prior experience at
 Cardinal and as a consultant to pharmaceutical manufacturers," as assets
 that, "should benefit the board." Glass Lewis agreed, stating that,
 "unaffiliated common shareholders would be best served with more robust
 oversight provided by the Costa Brava nominees."
     Corporate Governance
     Both firms expressed concern over the corporate governance practices at
 Bradley and the effect those practices have had in eroding shareholder
 value. Glass Lewis stated that, "the decline in the Company's value is
 attributable to the material weaknesses, financial restatements, and a SEC
 investigation that hang over an otherwise growing and profitable business."
 ISS noted that "Bradley has suffered from governance issues," specifically
 pointing out that "the company did not file any 10-Q or 10-K statements
 with the SEC during the entire 2005 and is currently subject to an informal
 SEC investigation." Glass Lewis affirmed their belief that, "the election
 of new directors to the board would be beneficial for unaffiliated
 shareholders."
     Executive Compensation:
     ISS and Glass Lewis each raised a red flag over the compensation paid
 to executives while shareholder value declined. ISS noted that, "while
 there was very limited information about the company's financial
 performance, key executives including Daniel Glassman and his son Bradley
 Glassman received significant salary increases." ISS went on to say, "[W]e
 find it difficult to justify the salary increases, especially during a
 period when there were no SEC filings regarding the company's financial
 performance."
     Glass Lewis gave Bradley a grade of "F" in executive compensation, and
 they noted that, "the Company paid more than its peers, but performed worse
 than its peers."
     Glass Lewis based their recommendation in part on the belief that, "the
 Costa Brava nominees will likely cause the board to review its compensation
 practices, more closely aligning its executive compensation with the
 Company's performance."
     Director Independence:
     ISS and Glass Lewis expressed concern over entrenched management
 control of the board of directors and the corresponding lack of
 accountability for management's empty promises. Glass Lewis stated that,
 "accountability has been lacking from the Bradley board of directors."
     ISS noted that this will not likely change if Bradley's current
 nominees are elected, stating that the election of Mr. Stagnaro and Mr.
 Whitehead may "further entrench management's control of the board."
     ISS and Glass Lewis echoed the same concerns that we have been sharing
 with shareholders throughout this proxy contest. Yet there is a reason we
 are the largest shareholder. We believe that these corporate governance
 issues and lack of accountability by management have held Bradley back from
 becoming a better company. If elected, our nominees will work
 constructively with their fellow board members to improve Bradley's
 corporate governance, tighten financial controls, lower product returns and
 maximize value for all shareholders.
     We urge you to cast your vote by using your touch tone phone or via the
 internet by following the instructions on your BLUE proxy card. You may
 also cast your vote for Costa Brava's nominees by signing, dating and
 returning the BLUE proxy card you received in the mail. But, we urge you to
 vote by phone or internet to ensure that your shares are represented at the
 meeting. Please vote today.
     Remember, only your latest dated proxy counts. If you have previously
 voted a proxy sent to you by Bradley, you have every right to change your
 vote and support Costa Brava's nominees by executing a later dated BLUE
 proxy using any of the methods listed above.
     If you have questions about our campaign or require help voting your
 shares, we urge you to call our proxy solicitors, MacKenzie Partners, Inc.,
 toll-free at 800-322-2885 or 212-929-5500 (call collect). You may also
 email questions to savebradley@mackenziepartners.com.
     Thank you for your support.
 
                                             Sincerely,
 
                                             COSTA BRAVA PARTNERSHIP III, L.P.
     Permission to use quotations from the ISS report and the Glass Lewis
 report was neither sought nor obtained.
     COSTA BRAVA PARTNERSHIP III L.P., ROARK, REARDEN & HAMOT, LLC, ROARK,
 REARDEN & HAMOT CAPITAL MANAGEMENT, LLC, SETH W. HAMOT, DOUGLAS E. LINTON
 AND JOHN S. ROSS (COLLECTIVELY, THE "PARTICIPANTS") FILED A DEFINITIVE
 PROXY STATEMENT AND ACCOMPANYING FORM OF PROXY WITH THE UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION ("SEC") ON SEPTEMBER 29, 2006, TO BE
 USED TO SOLICIT VOTES FOR THE ELECTION OF ITS SLATE OF DIRECTOR NOMINEES
 AND CERTAIN BUSINESS PROPOSALS FOR USE AT THE 2006 ANNUAL MEETING OF
 STOCKHOLDERS OF BRADLEY PHARMACEUTICALS, INC. INFORMATION RELATING TO THE
 PARTICIPANTS IS SET FORTH IN THE DEFINITIVE PROXY STATEMENT FILED WITH THE
 SEC.
     STOCKHOLDERS ARE ADVISED TO READ THE DEFINITIVE PROXY STATEMENT AND
 OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY CONTAIN
 IMPORTANT INFORMATION.
     THE DEFINITIVE PROXY STATEMENT, FORM OF PROXY AND OTHER PROXY MATERIALS
 ARE AVAILABLE AT NO CHARGE AT THE SECURITIES AND EXCHANGE COMMISSION'S
 WEBSITE AT HTTP://WWW.SEC.GOV.
 
 

SOURCE Costa Brava Partnership III, L.P.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.